Supporting materials

Supplementary models
Details of the individual patient data network meta-analysis models including treatment by covariate interactions that were applied are given below.
Notation
Let i denote the trial where and NS is the number of independent trials; let j the patient where such that is the number of patients in trial i; and let k be the trial arm where and is the number of arms in trial i.
Suppose if patient j in trial i in arm k experiences the event and if patient j in trial i in arm k does not experience the event. Assume that the outcomes of patients, ,
are independent and distributed as where is the probability of an event for patient j in trial i in arm k. Let be a patient-level covariate for patient j in trial i in arm k (such as, a continuous covariate value or an indicator variable for a dichotomous covariate).
Let denote the treatment given in trial i in arm k where and NT is the number of treatments in the network. Also specify that the node being split is ( , ) where and For example, if one wants to split the node (3, 4) then and .
Model S1. NMA model including treatment by covariate interaction
Assuming no multi-arm trials exist, the random-effects model is given as follows:
where is the log odds of an event in arm 1 of trial i; is a study-specific regression parameter that represents the difference in the log odds of an event in arm 1 of trial i per unit increase in the covariate ; represents the difference in the log odds ratio of vs.
per unit increase in the covariate and = -; and represents the trialspecific log odds ratio of vs. . The trial-specific log odds ratios, are assumed to be realisations from a normal distribution where and In this model, represents the log odds ratio of vs. . The fixed-effect model is given by setting Under a Bayesian framework, prior distributions are specified for , , , and
The model can also be applied to datasets with multi-arm trials but the correlation between trial-specific treatment effects must be taken into account. For each multi-arm trial i with m arms, the trial-specific treatment effects are taken to be a realisation from a multivariate normal distribution that can be decomposed into a series of conditional univariate normal distributions.
Model S2. NMA node-splitting model including treatment by covariate interaction
When there are no multi-arm trials, the random-effects model is specified as follows:
and where represents the difference in the log odds ratio of vs. per unit increase in the covariate estimated using direct evidence; represents the difference in the log odds ratio of vs. per unit increase in the covariate estimated using all trials that did not allocate and (i.e. using indirect evidence); and represents the trial-specific log odds ratio of vs. . The trial-specific log odds ratios, are assumed to be realisations from Under a Bayesian framework, prior distributions are specified for , , ,
Multiple node-splitting models are usually applied. One model can be applied for each comparison providing both direct and indirect evidence are available for that comparison.
Node-splitting models can accommodate multi-arm trials as described elsewhere (Dias et al., 2010a , van Valkenhoef et al., 2016 for treatment 3, and for treatment 4 where .
Code for Model S1
Winbugs code (saved as winbugs file "NMA RE IPD COVM1.odc")
Dataset 1 (saved a csv file"utf_ipdacc.csv") #t1= treatment in arm 1, t2=treatment in arm 2, t3=treatment in arm 3. #na=number of arms #Note that each row represents one study and the studies are in the same order as in dataset 2. t1  t2  t3  na  1  2  NA  2  1  2  NA  2  1  2  3  3  1  2  3  3  1  2  3  3  1  2  3  3  1  2  3  3  1  2  4 #LIST DATA FOR ENTRY INTO WINBUGS data= list("y", "s","arm", "tipd", "b", "x", "z", "mx", "t", "na", "ns","nt", "np", "nz") #WINBUGS MODEL Models1 = bugs (data, inits1, model.file= "NMA RE IPD COVM1.odc", parameters.to.save= c("mu", "d", "totresdev", "or", "lor", "sd", "tausq", "dz", "betas", "beta", "orz", "lorz", "beta0"), n.chains=1, n.iter=300000, n.burnin=100000, n.thin=5,codaPkg=FALSE, bugs. #LIST DATA FOR ENTRY INTO WINBUGS bugs.data(list("y"=y,"s"=s,"tipd"=tipd, "na" = na, "nt" = nt, "ns" = ns,"np" = np, "t"=t, "split" = checkPair[,"split"], "m" =m, "bi" = bi, "si" = si, "pair" = pair, "x"=x, "z"=z, "nz"=nz,"mx"=mx ) )
#WINBUGS MODEL modelS2=bugs(data = "data.txt", inits = inits1, parameters.to.save = c("direct", "d", "lor", "mu", "prob","totresdev", "diff", "directbeta", "directz", "lorz", "betas", "dz","beta", "sd", "tausq"), model.file = "NMA RE IPD DSPLIT BETASPLIT.odc", n.chains = 1, n.iter = 300000, n.burnin = 100000, bugs.directory = "C: Table S1 . Summary of the individual patient data (i.e. event rate of each treatment group of each site for treatment success at day 28) and covariate information. AQ+AS: amodiaquine-artesunate; AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate; DHAPQ: dihydroartemisininpiperaquine. Figure S2 . Posterior distributions of log odds ratios at various ages for treatment success for CD+A versus AL.
The mean age was 2.5 years.
AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate.
Posterior median (95% credibility interval) presented.
